Investor Relations


Advaxis, Inc. (NASDAQ: ADXS)

Advaxis is a clinical-stage biotechnology company focused on the development of immunotherapies to treat multiple different types of cancers. We are currently conducting clinical trials with our lead product candidate, ADXS-HPV, in HPV-associated cervical cancer (late-stage trials), head and neck cancer (Phase 1/2) and anal cancer (Phase 1). Our second lead product candidate is ADXS-cHER2, which we intend to develop for pediatric osteosarcoma and other HER2 overexpressing cancers, such as breast cancer. We intend to develop our third product candidate, ADXS-PSA, for prostate cancer, as well as explore the potential to combine any of our proprietary immunotherapies in combination with other anticancer therapies. Advaxis has three commercial partnerships with other major biopharmaceutical companies for the development and commercialization of our proprietary cancer immunotherapies in countries outside the U.S. and for the global animal-health oncology market. Advaxis has created and is developing more than 20 distinct immunotherapies based on its proprietary Lm TechnologyTM, either directly or through strategic collaborations with recognized cancer centers of excellence.

Recent News

Advaxis's Scientific Founder to Present on ADXS-HER2 at World Congress on Breast Cancer 2015

Read More

Advaxis Expands Intellectual Property for Lm Technology(TM) Platform in HER2

Read More

Advaxis Appoints Dr. Shelonitda S. Rose as Vice President, Clinical Development

Read More

Upcoming Events

2015 World Congress on Breast Cancer

August 4, 2015 at 9:00 am BST

Location: Birmingham, UK